GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycotopia Therapies Inc (OTCPK:TPIA) » Definitions » Forward PE Ratio

TPIA (Mycotopia Therapies) Forward PE Ratio : 0.00 (As of Dec. 15, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Mycotopia Therapies Forward PE Ratio?

Mycotopia Therapies's Forward PE Ratio for today is 0.00.

Mycotopia Therapies's PE Ratio without NRI for today is 0.00.

Mycotopia Therapies's PE Ratio (TTM) for today is 0.00.


Mycotopia Therapies Forward PE Ratio Historical Data

The historical data trend for Mycotopia Therapies's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycotopia Therapies Forward PE Ratio Chart

Mycotopia Therapies Annual Data
Trend
Forward PE Ratio

Mycotopia Therapies Quarterly Data
Forward PE Ratio

Competitive Comparison of Mycotopia Therapies's Forward PE Ratio

For the Biotechnology subindustry, Mycotopia Therapies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mycotopia Therapies's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mycotopia Therapies's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Mycotopia Therapies's Forward PE Ratio falls into.



Mycotopia Therapies Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Mycotopia Therapies  (OTCPK:TPIA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Mycotopia Therapies Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Mycotopia Therapies's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycotopia Therapies Business Description

Traded in Other Exchanges
N/A
Address
100 SE 2nd Street, Suite 2000, Miami, FL, USA, 33131
Mycotopia Therapies Inc provides psychedelic therapies treatment of mental health issues and supports the creation of both natural and synthetic molecules for the development of appropriate treatments.
Executives
Mark D. Williams director, 10 percent owner, officer: President, CEO & CFO 480 22ND STREET, BOX 2, HEYBURN ID 83336
Gibson Colin director, 10 percent owner, officer: Vice President 480 22ND STREET, BOX 2, HEYBURN ID 83336

Mycotopia Therapies Headlines

From GuruFocus

Four Top Psychedelic Stock Picks for 2021

By Marketwired Marketwired 01-04-2021

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

By Value_Insider Value_Insider 12-07-2022